We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the government. The 13F filings show the funds’ and investors’ portfolio positions as of September 30. In this article we look at what those investors think of Ampliphi Biosciences Corp (NYSEMKT:APHB).
Ampliphi Biosciences Corp (NYSEMKT:APHB) has experienced an increase in support from the world’s most elite money managers of late. APHB managed to capture the attention of some large investors as it was included in 6 hedge funds’ portfolios at the end of September, as compared to the previous quarter, when none of the funds in our database reported APHB positions. At the end of this article we will also compare APHB to other stocks, including Pacific Sunwear of California, Inc. (NASDAQ:PSUN), Paragon Offshore PLC (NYSE:PGN), and Amedica Corporation (NASDAQ:AMDA) to get a better sense of its popularity.
If you’d ask most stock holders, hedge funds are assumed to be worthless, outdated investment vehicles of yesteryear. While there are more than 8000 funds trading at present, Our experts hone in on the masters of this club, approximately 700 funds. It is estimated that this group of investors shepherd the lion’s share of all hedge funds’ total capital, and by following their finest investments, Insider Monkey has discovered various investment strategies that have historically outpaced the broader indices. Insider Monkey’s small-cap hedge fund strategy outrun the S&P 500 index by 12 percentage points per year for a decade in their back tests.
Keeping this in mind, we’re going to analyze the recent action regarding Ampliphi Biosciences Corp (NYSEMKT:APHB).
Hedge fund activity in Ampliphi Biosciences Corp (NYSEMKT:APHB)
According to Insider Monkey’s hedge fund database, Kevin Kotler’s Broadfin Capital has the number one position in Ampliphi Biosciences Corp (NYSEMKT:APHB), worth close to $2.2 million, accounting for 0.1% of its total 13F portfolio. The second most bullish fund is MSDC Management, led by Marc Lisker, Glenn Fuhrman and John Phelan, holding a $1.1 million position; less than 0.1%% of its 13F portfolio is allocated to the company. Other hedge funds and institutional investors that are bullish encompass Steven Boyd’s Armistice Capital, Joseph Edelman’s Perceptive Advisors and Peter Kolchinsky’s RA Capital Management.
Let’s now review hedge fund activity in other stocks similar to Ampliphi Biosciences Corp (NYSEMKT:APHB). These stocks are Pacific Sunwear of California, Inc. (NASDAQ:PSUN), Paragon Offshore PLC (NYSE:PGN), Amedica Corporation (NASDAQ:AMDA), and ParkerVision, Inc. (NASDAQ:PRKR). This group of stocks’ market values are similar to APHB’s market value.
|Ticker||No of HFs with positions||Total Value of HF Positions (x1000)||Change in HF Position|
As you can see these stocks had an average of 6 hedge funds with bullish positions and the average amount invested in these stocks was $2 million. That figure was $4 million in APHB’s case. Paragon Offshore PLC (NYSE:PGN) is the most popular stock in this table. On the other hand, Amedica Corporation (NASDAQ:AMDA) is the least popular one with only 4 bullish hedge fund positions. Ampliphi Biosciences Corp (NYSEMKT:APHB) is not the least popular stock in this group, but hedge fund interest is still below average. This is a slightly negative signal and we’d rather spend our time researching stocks that hedge funds are piling on. In this regard PGN might be a better candidate to consider a long position.